IndieBio is the world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.